Concepedia

Matthew A. Marx

MA

Statistics

Publications

32

Citations

4.5K

H-Index

23

Active since

1986

Affiliations

Pfizer (United States)(Current)

Mirati Therapeutics (United States)

Array BioPharma (United States)

The University of Texas at Austin

Neurocrine Biosciences (United States)

Matthew A. Marx is an author at Pfizer (United States) specializing in pharmacology, natural sciences, and drug discovery.

ORCID

Top concepts

Publications per year

1986–2024

32

Publications

32

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.2K citations · Full text

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 644 citations · Full text

Identification of the Clinical Development Candidate <b>MRTX849</b>, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer

Jay B. Fell, John P. Fischer, Brian R. Baer et al. · Journal of Medicinal Chemistry · 2020 · 559 citations · Full text

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

, , +7

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer

Lars D. Engstrom, Ruth Aranda, Laura Waters et al. · Cancer Discovery · 2023 · 163 citations · Full text

1–5 of 32